$BMRN
BIOMARIN PHARMACEUTICAL INC

2016 Q4 Form 10-Q Financial Statement

#000156459016027187 Filed on November 03, 2016

View on sec.gov

Income Statement

Concept 2016 Q4 2016 Q3 2015 Q3
Revenue $300.1M $278.3M $208.9M
YoY Change 31.68% 33.2% 18.33%
Cost Of Revenue $64.10M $50.70M $36.72M
YoY Change 50.47% 38.08% 22.72%
Gross Profit $235.9M $229.2M $172.2M
YoY Change 27.31% 33.11% 17.43%
Gross Profit Margin 78.61% 82.37% 82.42%
Selling, General & Admin $147.1M $119.6M $94.04M
YoY Change 31.34% 27.17% 26.06%
% of Gross Profit 62.36% 52.18% 54.62%
Research & Development $175.2M $160.8M $158.7M
YoY Change -0.51% 1.31% 26.28%
% of Gross Profit 74.27% 70.16% 92.18%
Depreciation & Amortization $20.10M $23.20M $12.70M
YoY Change 957.89% 82.68% 13.39%
% of Gross Profit 8.52% 10.12% 7.38%
Operating Expenses $329.8M $288.1M $252.8M
YoY Change 11.23% 13.98% 26.2%
Operating Profit -$93.90M -$60.09M -$81.87M
YoY Change -15.56% -26.61% -830.81%
Interest Expense -$2.800M $9.980M $9.447M
YoY Change -108.36% 5.64% 3.61%
% of Operating Profit
Other Income/Expense, Net $4.400M $1.700M -$300.0K
YoY Change -2300.0% -666.67% 200.0%
Pretax Income -$92.20M -$66.81M -$90.44M
YoY Change -199.14% -26.13% -2907.92%
Income Tax -$13.50M -$24.02M $483.0K
% Of Pretax Income
Net Earnings -$78.70M -$42.80M -$90.93M
YoY Change -214.72% -52.93% -1321.3%
Net Earnings / Revenue -26.22% -15.38% -43.53%
Basic Earnings Per Share -$0.22 -$0.57
Diluted Earnings Per Share -$457.3K -$0.22 -$0.60
COMMON SHARES
Basic Shares Outstanding 172.0M 167.7M 160.9M
Diluted Shares Outstanding 167.7M 161.1M

Balance Sheet

Concept 2016 Q4 2016 Q3 2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $789.7M $1.035B $618.4M
YoY Change 33.26% 67.34% -7.2%
Cash & Equivalents $408.3M $707.3M $376.3M
Short-Term Investments $381.3M $327.5M $242.1M
Other Short-Term Assets $61.70M $68.40M $115.3M
YoY Change 2.19% -40.69% 104.28%
Inventory $355.1M $347.4M $262.1M
Prepaid Expenses $73.17M
Receivables $215.3M $215.9M $148.9M
Other Receivables $0.00 $0.00 $12.70M
Total Short-Term Assets $1.422B $1.667B $1.176B
YoY Change 30.48% 41.77% 9.07%
LONG-TERM ASSETS
Property, Plant & Equipment $798.8M $737.1M $604.5M
YoY Change 13.43% 21.93% 24.2%
Goodwill $202.4M
YoY Change 273.02%
Intangibles $920.9M
YoY Change 475.77%
Long-Term Investments $572.7M $363.0M $514.4M
YoY Change 34.53% -29.43% 14.54%
Other Assets $479.6M $317.2M $60.79M
YoY Change 17.36% 421.8% -1.21%
Total Long-Term Assets $2.602B $2.176B $2.449B
YoY Change -1.43% -11.17% 79.75%
TOTAL ASSETS
Total Short-Term Assets $1.422B $1.667B $1.176B
Total Long-Term Assets $2.602B $2.176B $2.449B
Total Assets $4.024B $3.842B $3.625B
YoY Change 7.89% 6.0% 48.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $198.5M $145.4M $162.9M
YoY Change 6.61% -10.74% 332.22%
Accrued Expenses $158.9M $133.6M $115.4M
YoY Change -19.71% 15.77% 47.83%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $22.50M $22.50M
YoY Change
Total Short-Term Liabilities $439.3M $377.3M $390.5M
YoY Change -1.38% -3.38% 89.05%
LONG-TERM LIABILITIES
Long-Term Debt $660.8M $653.2M $667.8M
YoY Change -0.23% -2.19% 1.66%
Other Long-Term Liabilities $42.03M $165.9M $45.85M
YoY Change -5.73% 261.81% 74.61%
Total Long-Term Liabilities $42.03M $819.1M $45.85M
YoY Change -5.73% 1686.36% 74.61%
TOTAL LIABILITIES
Total Short-Term Liabilities $439.3M $377.3M $390.5M
Total Long-Term Liabilities $42.03M $819.1M $45.85M
Total Liabilities $1.257B $1.196B $1.332B
YoY Change -5.35% -10.19% 42.94%
SHAREHOLDERS EQUITY
Retained Earnings -$1.521B -$1.090B
YoY Change 48.84% 39.77%
Common Stock $4.288B $3.372B
YoY Change 25.57% 47.95%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.766B $2.646B $2.293B
YoY Change
Total Liabilities & Shareholders Equity $4.024B $3.842B $3.625B
YoY Change 7.89% 6.0% 48.53%

Cashflow Statement

Concept 2016 Q4 2016 Q3 2015 Q3
OPERATING ACTIVITIES
Net Income -$78.70M -$42.80M -$90.93M
YoY Change -214.72% -52.93% -1321.3%
Depreciation, Depletion And Amortization $20.10M $23.20M $12.70M
YoY Change 957.89% 82.68% 13.39%
Cash From Operating Activities -$200.0K -$10.30M -$2.900M
YoY Change -99.7% 255.17% -64.2%
INVESTING ACTIVITIES
Capital Expenditures -$51.60M -$26.10M -$44.50M
YoY Change -50.34% -41.35% 80.89%
Acquisitions
YoY Change
Other Investing Activities -$258.1M -$300.8M -$18.50M
YoY Change -240.73% 1525.95% -88.6%
Cash From Investing Activities -$309.6M -$326.9M -$63.00M
YoY Change -489.43% 418.89% -66.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 19.90M 737.0M 3.800M
YoY Change 109.47% 19294.74% -57.3%
NET CHANGE
Cash From Operating Activities -200.0K -10.30M -2.900M
Cash From Investing Activities -309.6M -326.9M -63.00M
Cash From Financing Activities 19.90M 737.0M 3.800M
Net Change In Cash -289.9M 399.8M -62.10M
YoY Change -1349.57% -743.8% -66.63%
FREE CASH FLOW
Cash From Operating Activities -$200.0K -$10.30M -$2.900M
Capital Expenditures -$51.60M -$26.10M -$44.50M
Free Cash Flow $51.40M $15.80M $41.60M
YoY Change 34.91% -62.02% 152.12%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
164959000
CY2015Q4 us-gaap Inventory Net
InventoryNet
271683000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
397040000
CY2015Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
0
CY2016Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
171987437
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2015Q4 us-gaap Short Term Investments
ShortTermInvestments
195579000
CY2016Q3 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
0
CY2016Q3 us-gaap Common Stock Issued Employee Trust Deferred
CommonStockIssuedEmployeeTrustDeferred
14969000
CY2015Q4 us-gaap Common Stock Issued Employee Trust Deferred
CommonStockIssuedEmployeeTrustDeferred
13616000
us-gaap Contracts Revenue
ContractsRevenue
849000
us-gaap Royalty Revenue
RoyaltyRevenue
4334000
us-gaap Royalty Revenue
RoyaltyRevenue
3008000
CY2016Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-45167000
CY2015Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-98203000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-247689000
us-gaap Revenues
Revenues
816763000
us-gaap Revenues
Revenues
661959000
us-gaap Cost Of Revenue
CostOfRevenue
145473000
us-gaap Cost Of Revenue
CostOfRevenue
103965000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
486663000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
458688000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
333635000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
288364000
bmrn Intangible Asset Amortization And Contingent Consideration
IntangibleAssetAmortizationAndContingentConsideration
-34318000
bmrn Intangible Asset Amortization And Contingent Consideration
IntangibleAssetAmortizationAndContingentConsideration
22963000
CY2016Q3 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
0
CY2015Q3 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
0
us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
599118000
us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
0
CY2016Q3 us-gaap Costs And Expenses
CostsAndExpenses
339981000
CY2015Q3 us-gaap Costs And Expenses
CostsAndExpenses
290777000
us-gaap Costs And Expenses
CostsAndExpenses
1530571000
us-gaap Costs And Expenses
CostsAndExpenses
873980000
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-60085000
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-81873000
us-gaap Operating Income Loss
OperatingIncomeLoss
-713808000
us-gaap Operating Income Loss
OperatingIncomeLoss
-212021000
CY2016Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-104000
CY2015Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-186000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-374000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-539000
CY2016Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1633000
CY2015Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1344000
us-gaap Investment Income Interest
InvestmentIncomeInterest
4561000
us-gaap Investment Income Interest
InvestmentIncomeInterest
3050000
CY2016Q3 us-gaap Interest Expense
InterestExpense
9980000
CY2015Q3 us-gaap Interest Expense
InterestExpense
9447000
us-gaap Interest Expense
InterestExpense
29767000
us-gaap Interest Expense
InterestExpense
28911000
CY2016Q3 us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
0
CY2015Q3 us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
0
us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
0
us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
163000
CY2016Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
1723000
CY2015Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-281000
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
504000
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-9105000
CY2016Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-66813000
CY2015Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-90443000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-738884000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
76805000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
34301000
us-gaap Gain Loss On Sale Of Equity Investments
GainLossOnSaleOfEquityInvestments
3022000
us-gaap Asset Impairment Charges
AssetImpairmentCharges
599118000
us-gaap Asset Impairment Charges
AssetImpairmentCharges
12802000
CY2016Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-24016000
CY2015Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
483000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-187385000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-7273000
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-42797000
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-90926000
us-gaap Net Income Loss
NetIncomeLoss
-551499000
us-gaap Net Income Loss
NetIncomeLoss
-240416000
CY2016Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.26
CY2015Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.57
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.36
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.51
CY2016Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.26
CY2015Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.60
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.37
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.51
CY2016Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
167714000
CY2015Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
160886000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
163963000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
159647000
CY2016Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
167714000
CY2015Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
161134000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
164216000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
159647000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-18875000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
712938000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
6048000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
43450000
us-gaap Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation
AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation
563000
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
55241000
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments
StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments
8924000
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
-1353000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
100006000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
22276000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
21243000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-681000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1616000
us-gaap Share Based Compensation
ShareBasedCompensation
97220000
us-gaap Share Based Compensation
ShareBasedCompensation
80959000
us-gaap Gain Loss On Sale Of Equity Investments
GainLossOnSaleOfEquityInvestments
-2020000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-206691000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
14629000
us-gaap Excess Tax Benefit From Share Based Compensation Operating Activities
ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
563000
us-gaap Excess Tax Benefit From Share Based Compensation Operating Activities
ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
463000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
10961000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
16491000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-56954000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
15101000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-1044000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
888257000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
712938000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-1059000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
52023000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-146000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
59802000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
47469000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
1556000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
27970000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
5002000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
1391000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-77852000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
924000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-4451000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
790000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-228190000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-153652000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
96806000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
123844000
bmrn Payment For Escrow Deposit
PaymentForEscrowDeposit
8383000
bmrn Payment For Escrow Deposit
PaymentForEscrowDeposit
12500000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
302801000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
261786000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
370393000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
842873000
us-gaap Origination Of Notes Receivable From Related Parties
OriginationOfNotesReceivableFromRelatedParties
0
us-gaap Origination Of Notes Receivable From Related Parties
OriginationOfNotesReceivableFromRelatedParties
3326000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
1467000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
538392000
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
150000
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
0
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-174398000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-1259149000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
49498000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
51515000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
55241000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
21968000
us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
563000
us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
463000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
0
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-2062000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
707758000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
916205000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
5139000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-2544000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
310309000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-499140000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
875486000
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
376346000
us-gaap Interest Paid Net
InterestPaidNet
4564000
us-gaap Interest Paid Net
InterestPaidNet
4979000
us-gaap Income Taxes Paid
IncomeTaxesPaid
95163000
us-gaap Income Taxes Paid
IncomeTaxesPaid
15377000
bmrn Stock Based Compensation Capitalized
StockBasedCompensationCapitalized
8960000
bmrn Stock Based Compensation Capitalized
StockBasedCompensationCapitalized
8271000
bmrn Depreciation Expense Capitalized Into Inventory
DepreciationExpenseCapitalizedIntoInventory
13402000
bmrn Depreciation Expense Capitalized Into Inventory
DepreciationExpenseCapitalizedIntoInventory
11005000
bmrn Supplemental Accounts Payable And Accrued Liabilities Increase Decrease
SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecrease
-13988000
bmrn Supplemental Accounts Payable And Accrued Liabilities Increase Decrease
SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecrease
-11386000
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
8924000
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
8957000
us-gaap Noncash Or Part Noncash Acquisition Inventory Acquired1
NoncashOrPartNoncashAcquisitionInventoryAcquired1
1322000
us-gaap Noncash Or Part Noncash Acquisition Inventory Acquired1
NoncashOrPartNoncashAcquisitionInventoryAcquired1
0
us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(1) NATURE OF OPERATIONS AND BUSINESS RISKS</p> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">BioMarin Pharmaceutical Inc. (the Company), a Delaware corporation, develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The Company selects product candidates for diseases and conditions that represent a significant unmet medical need, have well-understood biology and provide an opportunity to be first-to-market or offer a significant benefit over existing products. The Company&#8217;s product portfolio consists of five approved products and multiple clinical and investigational product candidates. The Company&#8217;s approved products are Vimizim (elosulfase alfa), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company expects to continue to finance future cash needs that exceed its operating activities primarily through its current cash, cash equivalents, short-term and long-term investments and, to the extent appropriate, through proceeds from equity or debt financings, loans and collaborative agreements with corporate partners. Until the Company consistently generates positive cash flows from its operations, the Company expects to raise the capital necessary to fund its current operations and long-term plans. Additional capital may also be necessary if the Company enters into potential licenses and other acquisitions of complementary technologies, products or companies. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to a number of risks and uncertainties, including, without limitation: the financial performance of its approved products; the expected need for additional financings; the Company&#8217;s ability to successfully commercialize its approved products; the uncertainty of the Company&#8217;s research and development (R&amp;D) efforts resulting in future successful commercial products; the Company&#8217;s ability to successfully obtain regulatory approval for new products; the Company&#8217;s ability to compete effectively; reliance on the proprietary technology of others; dependence on key personnel; uncertain patent protection; dependence on corporate partners and collaborators; and possible restrictions on reimbursement from governmental agencies and healthcare organizations, as well as other changes in the health care industry. </p></div>
us-gaap Basis Of Accounting
BasisOfAccounting
<div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(2) BASIS OF PRESENTATION</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The accompanying Condensed Consolidated Financial Statements have been prepared pursuant to the rules and regulations of the SEC for Quarterly Reports on Form 10-Q and do not include all of the information and note disclosures required by the United States generally accepted accounting principles (U.S. GAAP) for complete financial statements, although the Company believes that the disclosures herein are adequate to ensure that the information presented is not misleading. The Condensed Consolidated Financial Statements should therefore be read in conjunction with the Consolidated Financial Statements and Notes thereto for the fiscal year ended December&#160;31, 2015 included in the Company&#8217;s Annual Report on Form 10-K.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying Condensed Consolidated Financial Statements have been prepared in accordance with U.S. GAAP, which requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying disclosures. Although these estimates are based on management&#8217;s best knowledge of current events and actions that the Company may undertake in the future, actual results may be different from those estimates. The Condensed Consolidated Financial Statements reflect all adjustments of a normal, recurring nature that are, in the opinion of management, necessary for a fair presentation of results for these interim periods. The results of operations for the three&#160;and&#160;nine months ended September&#160;30, 2016 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2016 or any other period.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management performed an evaluation of the Company&#8217;s activities through the date of filing of this Quarterly Report on Form 10-Q, and has concluded that there were no subsequent events or transactions that occurred subsequent to the balance sheet date prior to filing this Quarterly Report on Form 10-Q that would require recognition or disclosure in the Condensed Consolidated Financial Statements.</p></div>
us-gaap Description Of New Accounting Pronouncements Not Yet Adopted
DescriptionOfNewAccountingPronouncementsNotYetAdopted
<div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(4) RECENT ACCOUNTING PRONOUNCEMENTS</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Except as described below, there have been no new accounting pronouncements or changes to accounting pronouncements during the nine months ended September&#160;30, 2016, as compared to the recent accounting pronouncements described in Note 4 of the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2015, that are of significance or potential significance to the Company.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2016, <font style="color:#000000;">the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-09, </font><font style="font-style:italic;color:#000000;">Improvements to Employee Share-Based Payment Accounting</font><font style="color:#000000;"> (ASU 2016-09), which is intended to simplify several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. </font>ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early application is permitted. <font style="color:#000000;">ASU 2016-09 will be effective for the Company&#8217;s fiscal year beginning January 1, 2017 unless it elects early adoption. </font>The Company is currently evaluating the potential impact the adoption of ASU 2016-09 will have on its consolidated financial statements and as of September 30, 2016, the Company has not made the election to early adopt the amendments.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, <font style="color:#000000;">the FASB issued ASU No. 2016-02, </font><font style="font-style:italic;color:#000000;">Leases</font><font style="color:#000000;"> (ASU 2016-02). The amended guidance requires balance sheet recognition of lease assets and liabilities by lessees for leases classified as operating leases, with an option to not recognize lease assets and lease liabilities for leases with a term of 12 months or less. The amendments also require new disclosures providing additional qualitative and quantitative information about the amounts recorded in the financial statements. Lessor accounting is largely unchanged.</font> ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted. <font style="color:#000000;">ASU 2016-02 will be effective for the Company&#8217;s fiscal year beginning January 1, 2019 unless it elects early adoption. The amendments require a modified retrospective approach with optional practical expedients. </font>The Company is currently evaluating the potential impact the adoption of ASU 2016-02 will have on its consolidated financial statements and has not made the election to early adopt ASU 2016-02.<font style="color:#000000;">&nbsp;&nbsp; </font></p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:5%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2014, the FASB issued ASU No. 2014-09 (ASU 2014-09) regarding Accounting Standards Codification (ASC) Topic 606, <font style="font-style:italic;">Revenue from Contracts with Customers</font>. ASU 2014-09 provides principles for recognizing revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. In August 2015, the FASB issued ASU No. 2015-14 to defer the effective date by one year with early adoption permitted as of the original effective date. ASU 2014-09 will be effective for the Company&#8217;s fiscal year beginning January 1, 2018 unless it elects the earlier date of January 1, 2017. In March 2016, the FASB issued ASU No. 2016-08 to help provide interpretive clarifications on the new guidance for ASC Topic 606. In April 2016, the FASB issued ASU No. 2016-10 to clarify the guidance for identifying performance obligations and accounting for licenses of intellectual property. In May 2016, the FASB issued ASU No. 2016-12 to improve the guidance on collectibility, noncash consideration, and completed contracts at transition. The Company is currently evaluating the accounting, transition, and disclosure requirements of the standard<font style="color:#000000;">.</font></p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p></div>
CY2015Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
622207000
CY2015Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
100000
CY2015Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1076000
CY2015Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
621231000
CY2015 bmrn Number Of Investments In Marketable Equity Securities
NumberOfInvestmentsInMarketableEquitySecurities
2
bmrn Number Of Products Approved
NumberOfProductsApproved
5
CY2016Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-42797000
CY2015Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-90926000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-551499000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-240416000
CY2016Q3 us-gaap Employee Stock Ownership Plan Esop Gain Loss On Transactions In Deferred Shares
EmployeeStockOwnershipPlanESOPGainLossOnTransactionsInDeferredShares
0
CY2015Q3 us-gaap Employee Stock Ownership Plan Esop Gain Loss On Transactions In Deferred Shares
EmployeeStockOwnershipPlanESOPGainLossOnTransactionsInDeferredShares
-4980000
us-gaap Employee Stock Ownership Plan Esop Gain Loss On Transactions In Deferred Shares
EmployeeStockOwnershipPlanESOPGainLossOnTransactionsInDeferredShares
-1753000
us-gaap Employee Stock Ownership Plan Esop Gain Loss On Transactions In Deferred Shares
EmployeeStockOwnershipPlanESOPGainLossOnTransactionsInDeferredShares
0
CY2016Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-42797000
CY2015Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-95906000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-553252000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-240416000
CY2016Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0
CY2015Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
248000
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
253000
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0
CY2016Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
21792000
CY2015Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
22008000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
21523000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
22123000
CY2016Q3 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
689477000
CY2016Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1145000
CY2016Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
167000
CY2016Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
690455000
CY2016Q2 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
-2000000
CY2016Q3 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
7300000
CY2015Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
18100000
CY2015Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
150289000
CY2016Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
110873000
CY2015Q4 bmrn Deposit For Business Acquisition
DepositForBusinessAcquisition
371756000
CY2016Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
19748000
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
278603000
CY2016Q3 us-gaap Depreciation
Depreciation
23200000
us-gaap Depreciation
Depreciation
56100000
CY2015Q3 us-gaap Depreciation
Depreciation
12700000
us-gaap Depreciation
Depreciation
36400000
CY2016Q3 bmrn Depreciation Expense Capitalized Into Inventory
DepreciationExpenseCapitalizedIntoInventory
4400000
CY2015Q3 bmrn Depreciation Expense Capitalized Into Inventory
DepreciationExpenseCapitalizedIntoInventory
3700000
CY2016Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
46951000
CY2015Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
46115000
CY2016Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
189596000
CY2015Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
75279000
CY2016Q3 bmrn Deposit For Business Acquisition
DepositForBusinessAcquisition
0
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
4300000
CY2015 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
12700000
CY2016Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
327499000
CY2015Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
195579000
CY2016Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
362956000
CY2015Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
425652000
CY2016Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
690455000
CY2015Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
621231000
us-gaap Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
0
CY2016Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
305122000
CY2015Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
129572000
CY2016Q3 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
332199000
CY2015Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
607548000
CY2016Q3 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
637321000
CY2015Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
737120000
CY2016Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
75934000
CY2015Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
53124000
CY2016Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1058030000
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
982810000
CY2016Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
328194000
CY2015Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
8606000
CY2016Q3 us-gaap Investments
Investments
7267000
CY2015Q4 us-gaap Investments
Investments
18056000
CY2016Q3 us-gaap Derivative Assets Noncurrent
DerivativeAssetsNoncurrent
750000
CY2015Q4 us-gaap Derivative Assets Noncurrent
DerivativeAssetsNoncurrent
3533000
CY2016Q3 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
8678000
CY2015Q4 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
6693000
CY2016Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
148773000
CY2015Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
179294000
CY2016Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
85219000
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
95345000
CY2016Q3 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
34184000
CY2015Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
32553000
CY2016Q3 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
14183000
CY2015Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
10412000
CY2016Q3 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
7961000
CY2015Q4 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
6377000
CY2016Q3 us-gaap Accrued Income Taxes
AccruedIncomeTaxes
0
CY2015Q4 us-gaap Accrued Income Taxes
AccruedIncomeTaxes
59572000
CY2016Q3 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
15809000
CY2015Q4 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
8958000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-2282000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
bmrn Contingent Payments Upon Achievement Of Certain Development And Regulatory Activities Commercial Sales And Licensing Milestones
ContingentPaymentsUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones
754400000
CY2015Q4 us-gaap Convertible Debt
ConvertibleDebt
662286000
CY2015Q4 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
1147301000
CY2016Q3 us-gaap Derivative Fair Value Of Derivative Asset
DerivativeFairValueOfDerivativeAsset
5560000
CY2016Q3 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
5334000
CY2015Q4 us-gaap Derivative Fair Value Of Derivative Asset
DerivativeFairValueOfDerivativeAsset
14011000
CY2015Q4 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
5065000
us-gaap Derivative Instruments Gain Loss Recognized In Other Comprehensive Income Effective Portion Net
DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet
1200000
CY2015 us-gaap Derivative Instruments Gain Loss Recognized In Other Comprehensive Income Effective Portion Net
DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet
13600000
CY2015Q4 us-gaap Asset Retirement Obligation
AssetRetirementObligation
4704000
us-gaap Asset Retirement Obligation Accretion Expense
AssetRetirementObligationAccretionExpense
79000
us-gaap Asset Retirement Obligation Revision Of Estimate
AssetRetirementObligationRevisionOfEstimate
-250000
CY2016Q3 us-gaap Asset Retirement Obligation
AssetRetirementObligation
4533000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
783580
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
41.15
CY2016Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
32902000
CY2015Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
28758000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
97220000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
80959000
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
9000000
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
8300000
CY2016Q3 us-gaap Oci Before Reclassifications Before Tax Attributable To Parent
OciBeforeReclassificationsBeforeTaxAttributableToParent
-247000
CY2016Q3 us-gaap Reclassification From Aoci Current Period Before Tax Attributable To Parent
ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
-1493000
CY2016Q3 us-gaap Other Comprehensive Income Loss Tax Portion Attributable To Parent1
OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
630000
CY2016Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-2370000
us-gaap Oci Before Reclassifications Before Tax Attributable To Parent
OciBeforeReclassificationsBeforeTaxAttributableToParent
-14333000
us-gaap Reclassification From Aoci Current Period Before Tax Attributable To Parent
ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
-6890000
us-gaap Other Comprehensive Income Loss Tax Portion Attributable To Parent1
OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
-2348000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-18875000
CY2015Q3 us-gaap Reclassification From Aoci Current Period Before Tax Attributable To Parent
ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
-5201000
CY2015Q3 us-gaap Other Comprehensive Income Loss Tax Portion Attributable To Parent1
OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
-2956000
CY2015Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-7277000
us-gaap Reclassification From Aoci Current Period Before Tax Attributable To Parent
ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
-18120000
us-gaap Other Comprehensive Income Loss Tax Portion Attributable To Parent1
OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
-779000
CY2016Q3 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
171400000
CY2016Q3 us-gaap Purchase Obligation
PurchaseObligation
50900000

Files In Submission

Name View Source Status
0001564590-16-027187-index-headers.html Edgar Link pending
0001564590-16-027187-index.html Edgar Link pending
0001564590-16-027187.txt Edgar Link pending
0001564590-16-027187-xbrl.zip Edgar Link pending
bmrn-10q_20160930.htm Edgar Link pending
bmrn-20160930.xml Edgar Link completed
bmrn-20160930.xsd Edgar Link pending
bmrn-20160930_cal.xml Edgar Link unprocessable
bmrn-20160930_def.xml Edgar Link unprocessable
bmrn-20160930_lab.xml Edgar Link unprocessable
bmrn-20160930_pre.xml Edgar Link unprocessable
bmrn-ex311_9.htm Edgar Link pending
bmrn-ex312_7.htm Edgar Link pending
bmrn-ex321_6.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending